HCM
NEUTRALHUTCHMED to Present R&D Updates on October 31 2025
The biopharmaceutical company will host an R&D update presentation and webcast on October 31, 2025, providing insights into its development pipeline.
HUTCHMED (China) Limited
254.00GBX
2.83%
Market Cap
2.21B
Volume
8.11k
16% of avg
P/E Ratio
8466.67
EPS (TTM)
0.03
Beta
0.47
Day Range
0.00p - 0.00p
52 Week Range
0.00p254.00p336.00p
254.00p
Upcoming Events
HCM
NEUTRALHUTCHMED Highlights Data to be Presented at CSCO
The biopharmaceutical company is presenting clinical data on several of its compounds at upcoming medical conferences.
HCM
NEUTRALHUTCHMED Announces Appointment of Acting Chief Executive Officer
The healthcare company has appointed an Acting Chief Executive Officer while the current CEO takes a leave of absence due to health reasons.
HCM
NEUTRALHUTCHMED Completes Enrollment of Phase III Trial
The biopharmaceutical company has completed patient enrollment for a Phase III clinical trial, a key milestone in the development of its cancer treatments.
HCM
NEUTRALHUTCHMED Reports Mixed H1 2025 Results with Revenue Decline and Increased Net Income
The biopharmaceutical firm reported mixed H1 2025 results, with revenue decline offset by a significant one-off gain. Despite cash position improvement, ongoing operational challenges and intensifying competition raise concerns about near-term performance.
HCM
NEUTRALHUTCHMED Announces 2025 Half-Year Results Webcast
The biopharmaceutical company will host webcast presentations to discuss its 2025 half-year financial results.
HCM
NEUTRALHUTCHMED Appoints New Joint Corporate Broker in London
The healthcare company has appointed Deutsche Bank AG as a new joint corporate broker in London.
HCM
NEUTRALHUTCHMED Announces China Approval for ORPATHYS® and TAGRISSO® Combination in Lung Cancer
The healthcare company has received approval in China for a new lung cancer treatment combination.
HCM
NEUTRALHUTCHMED Grants Share Options and LTIP Awards to Executives
The healthcare company has granted share options and LTIP awards to its executive team as part of its compensation and retention strategy.
HCM
GOODHUTCHMED and Innovent Announce NDA Acceptance for Fruquintinib and Sintilimab Combination in Renal Cell Carcinoma
The biopharmaceutical company has announced that its NDA for a combination therapy to treat advanced renal cell carcinoma has been accepted for review, marking a key milestone in bringing this potential new treatment option to patients.